Sangamo Historical Financial Ratios
| SGMO Stock | USD 1.04 0.04 4.00% |
Sangamo Therapeutics is promptly reporting on over 107 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Book Value Per Share of 0.41, Invested Capital of 0.0, Average Payables of 0.0 or Stock Based Compensation To Revenue of 0.32 will help investors to properly organize and evaluate Sangamo Therapeutics financial condition quickly.
Sangamo |
About Sangamo Financial Ratios Analysis
Sangamo TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Sangamo Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Sangamo financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Sangamo Therapeutics history.
Sangamo Therapeutics Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Sangamo Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Sangamo Therapeutics sales, a figure that is much harder to manipulate than other Sangamo Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Book Value Per Share
The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.Stock Based Compensation To Revenue
A metric that compares the total value of stock-based compensation granted by a company to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards.Most ratios from Sangamo Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Sangamo Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sangamo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.At this time, Sangamo Therapeutics' Stock Based Compensation To Revenue is very stable compared to the past year. As of the 8th of March 2025, Capex To Depreciation is likely to grow to 1.22, while Price To Sales Ratio is likely to drop 0.59.
| 2022 | 2023 | 2024 | 2025 (projected) | Days Sales Outstanding | 14.67 | 2.75 | 3.16 | 3.0 | PTB Ratio | 1.64 | 1.14 | 1.31 | 1.25 |
Sangamo Therapeutics fundamentals Correlations
Click cells to compare fundamentals
Sangamo Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Sangamo Therapeutics fundamentals Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Price To Sales Ratio | 17.75 | 9.79 | 4.35 | 0.54 | 0.62 | 0.59 | |
| Ptb Ratio | 4.22 | 2.89 | 1.64 | 1.14 | 1.31 | 1.25 | |
| Days Sales Outstanding | 19.33 | 20.98 | 14.67 | 2.75 | 3.16 | 3.0 | |
| Book Value Per Share | 3.7 | 2.6 | 1.91 | 0.48 | 0.43 | 0.41 | |
| Free Cash Flow Yield | 0.074 | (0.24) | (0.5) | (2.6) | (2.98) | (2.84) | |
| Operating Cash Flow Per Share | (1.29) | 1.26 | (1.61) | (1.45) | (1.48) | (1.41) | |
| Pb Ratio | 4.22 | 2.89 | 1.64 | 1.14 | 1.31 | 1.25 | |
| Ev To Sales | 17.0 | 8.61 | 3.84 | 0.5 | 0.57 | 0.54 | |
| Free Cash Flow Per Share | 1.15 | (1.77) | (1.58) | (1.41) | (1.62) | (1.54) | |
| Roic | (0.15) | (0.16) | (0.31) | (2.2) | (2.53) | (2.4) | |
| Inventory Turnover | (306.31) | (6.48) | (3.58) | (0.11) | (0.12) | (0.13) | |
| Net Income Per Share | (0.9) | (1.23) | (1.25) | (1.48) | (1.7) | (1.61) | |
| Days Of Inventory On Hand | (56.32) | (102.1) | (3.4K) | 3.0E-5 | 3.5E-5 | 3.6E-5 | |
| Payables Turnover | 14.39 | 0.97 | 0.54 | 14.52 | 13.07 | 12.41 | |
| Capex To Revenue | 0.2 | 0.12 | 0.21 | 0.18 | 0.11 | 0.096 | |
| Cash Per Share | 4.77 | 2.6 | 1.8 | 0.46 | 0.42 | 0.4 | |
| Pocfratio | 12.35 | (4.65) | (2.17) | (0.42) | (0.38) | (0.4) | |
| Capex To Operating Cash Flow | 0.0866 | (0.0998) | (0.0902) | (0.0941) | (0.0847) | (0.0804) | |
| Pfcf Ratio | 13.52 | (4.23) | (1.99) | (0.39) | (0.35) | (0.36) | |
| Days Payables Outstanding | 25.36 | 377.37 | 675.8 | 25.14 | 22.62 | 21.49 | |
| Income Quality | (1.4) | 1.31 | 1.16 | 0.87 | 0.78 | 0.42 | |
| Roe | (0.24) | (0.48) | (0.65) | (3.11) | (3.58) | (3.4) | |
| Ev To Operating Cash Flow | 11.83 | (4.09) | (1.91) | (0.39) | (0.35) | (0.37) | |
| Pe Ratio | (17.32) | (6.08) | (2.52) | (0.37) | (0.33) | (0.35) | |
| Ev To Free Cash Flow | 12.95 | (3.72) | (1.75) | (0.36) | (0.32) | (0.34) | |
| Earnings Yield | (0.0577) | (0.16) | (0.4) | (2.72) | (3.13) | (2.97) | |
| Net Debt To E B I T D A | 0.72 | 0.75 | 0.3 | 0.0812 | 0.0934 | 0.0887 | |
| Current Ratio | 4.6 | 3.12 | 2.69 | 1.98 | 2.27 | 2.16 | |
| Tangible Book Value Per Share | 2.95 | 1.95 | 1.34 | 0.48 | 0.43 | 0.41 | |
| Receivables Turnover | 18.88 | 17.4 | 24.89 | 132.9 | 119.61 | 125.6 | |
| Shareholders Equity Per Share | 3.7 | 2.6 | 1.91 | 0.48 | 0.43 | 0.41 | |
| Capex Per Share | 0.44 | 0.18 | 0.11 | 0.16 | 0.13 | 0.12 | |
| Graham Net Net | 1.34 | (0.0646) | 0.087 | (0.002502) | (0.002878) | (0.002734) |
Pair Trading with Sangamo Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sangamo Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sangamo Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Sangamo Stock
Moving against Sangamo Stock
| 0.71 | NBY | NovaBay Pharmaceuticals | PairCorr |
| 0.62 | ETON | Eton Pharmaceuticals | PairCorr |
| 0.5 | PFE | Pfizer Inc Aggressive Push | PairCorr |
| 0.48 | ZVSA | ZyVersa Therapeutics | PairCorr |
| 0.47 | VIGL | Vigil Neuroscience | PairCorr |
The ability to find closely correlated positions to Sangamo Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sangamo Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sangamo Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sangamo Therapeutics to buy it.
The correlation of Sangamo Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sangamo Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sangamo Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sangamo Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sangamo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sangamo Therapeutics. If investors know Sangamo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sangamo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.24) | Revenue Per Share | Quarterly Revenue Growth (0.95) | Return On Assets | Return On Equity |
The market value of Sangamo Therapeutics is measured differently than its book value, which is the value of Sangamo that is recorded on the company's balance sheet. Investors also form their own opinion of Sangamo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sangamo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sangamo Therapeutics' market value can be influenced by many factors that don't directly affect Sangamo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sangamo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sangamo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sangamo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.